FDA Guidance Boosts Legend Biotech's Market Prospects
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2026
0mins
Source: NASDAQ.COM
Legend Biotech Corp's stock has hit a 52-week low, declining by 15.20% in regular trading.
The recent FDA draft guidance allowing minimal residual disease and complete response as endpoints for accelerated approval in multiple myeloma treatments has generated optimism in the market. This is particularly beneficial for Legend Biotech, which is collaborating with Johnson & Johnson on the Carvykti cell therapy, incorporating MRD negativity as an endpoint in the CARTITUDE-6 trial. Analysts from Jefferies have maintained an Outperform rating on Legend Biotech, setting a target price of $66, indicating confidence in its future growth despite current price challenges.
The implications of the FDA guidance could enhance Legend Biotech's competitive position in the market, especially as it aligns with ongoing clinical trials and partnerships that may drive future stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LEGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LEGN
Wall Street analysts forecast LEGN stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 28.040
Low
48.00
Averages
68.10
High
90.00
Current: 28.040
Low
48.00
Averages
68.10
High
90.00
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech M&A Surge Resumes with Major Deals
- M&A Market Revival: According to a PwC report, the pharmaceutical and life sciences sector saw over $65 billion in mergers and acquisitions in Q1 2023, marking the best quarter since 2020 and indicating a significant uptick in market activity.
- Legend Biotech's Growth Potential: Legend Biotech's Carvykti therapy generated $597 million in sales in Q1, a 62% year-over-year increase, with projections suggesting annual sales could exceed $5 billion, making it an attractive acquisition target for larger pharmaceutical companies.
- BioNTech's Clinical Trial Progress: Despite a 35.4% year-over-year revenue decline to €118.1 million, BioNTech is running over 25 phase 2 and phase 3 clinical trials, showcasing a mature oncology portfolio that could attract acquisition interest.
- Acquisition Risks and Opportunities: Although both Legend Biotech and BioNTech have seen their shares drop over 13% in the past year, their unique technologies and product lines present significant potential upside for large pharmaceutical companies facing patent cliffs, making acquisitions a strategic consideration.
See More
Pharmaceutical Sector Sees $65 Billion in M&A Activity in Q1 2023
- M&A Activity Resurgence: According to PwC, the pharmaceutical and life sciences sector saw over $65 billion in mergers and acquisitions in Q1 2023, marking the best quarter since 2020 and indicating a robust recovery in the industry.
- Major Deal Examples: In Q2, Sun Pharmaceuticals announced its acquisition of Organon for $11.75 billion, while AbbVie reported its acquisition of Apogee Therapeutics for $10.9 billion in June, reflecting large pharma's strong interest in biotech companies and enhancing market activity.
- Market Potential of Legend Biotech: Legend Biotech's Carvykti therapy generated $597 million in sales in Q1, up 62% year-over-year, with projected annual sales potentially exceeding $5 billion, showcasing its competitive strength in the oncology treatment landscape.
- Financial Attractiveness of BioNTech: Despite a 35.4% year-over-year revenue decline to €118.1 million, BioNTech holds €16.8 billion in cash and equivalents, making it an appealing acquisition target, particularly with its mature oncology portfolio and upcoming clinical trials.
See More
Calidi Biotherapeutics Appoints New Independent Director
- New Board Member: Calidi Biotherapeutics announced the appointment of Corsee Sanders as an independent director effective June 17, 2026, leveraging her 23 years of leadership experience at Genentech/Roche to provide strategic guidance.
- Extensive Industry Background: Sanders previously served as Executive Vice President of Development Operations at Juno and acted as a strategic advisor to the Chief Medical Officer post-Celgene acquisition, highlighting her deep expertise in the biopharmaceutical sector.
- Current Board Positions: Currently, Sanders holds board positions at Legend Biotech, Ultragenyx Pharmaceutical, and AltruBio, further enhancing her influence within the biotechnology industry.
- Stock Price Fluctuation: Calidi's stock has traded between $0.12 and $19.20 over the past year, closing at $0.1560, indicating a cautious market sentiment regarding the company's future prospects.
See More
Stock Futures Rise Modestly; Rumble and Others Show Strong Performance
- Rumble's New Business Unit: Rumble (RUM) shares surged 17% after the company launched a new business unit following its acquisition of Northern Data AG, with FY revenue outlook raised by approximately 30% to between €170 million and €190 million, enhancing its competitive position in the market.
- Smith & Wesson's Strong Earnings: Smith & Wesson Brands (SWBI) saw a 14% increase in shares after reporting a quarterly performance that exceeded expectations, with net sales up nearly 27% year-over-year and adjusted EBITDAS rising 31.7%, while planning investments in its Springfield facility for FY 2027 to boost capacity and operational efficiency.
- Spero Therapeutics Drug Approval: Spero Therapeutics (SPRO) shares rose 11% following FDA approval of Utebzi, developed in partnership with GSK, marking the first oral carbapenem therapy for complicated urinary tract infections, which is expected to significantly increase its market share.
- D-Wave's Quantum Computing Simulator: D-Wave Quantum (QBTS) shares gained 4% after unveiling its first gate-model quantum computing simulator designed for error-aware programming, representing a technological advancement that may attract more developers to its innovative solutions.
See More
Legend Biotech Prices Public Offering of 7.7M ADSs
- Offering Size: Legend Biotech has announced the pricing of 7.7 million American Depositary Shares (ADSs) at $29.35 each, with total gross proceeds expected to be approximately $226 million, which will significantly bolster the company's capital structure.
- Underwriter Arrangement: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are acting as joint book-running managers for the transaction, indicating strong market confidence in the company's financing capabilities and laying the groundwork for future capital operations.
- Overallotment Option: Legend Biotech has granted underwriters a 30-day overallotment option to purchase up to an additional 1.16 million ADSs at the public offering price, providing the company with flexibility for further financing.
- Market Reaction: Following the announcement of the offering, Legend Biotech's shares fell 6% in after-hours trading on Wednesday, reflecting a cautious market sentiment regarding the financing, which may impact the company's short-term stock performance.
See More
Legend Biotech Prices Public Offering at $29.35 per ADS
- Offering Size: Legend Biotech has priced its public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 each, raising approximately $226 million in gross proceeds before underwriting discounts and expenses, indicating strong demand in the capital markets.
- Underwriter Arrangement: The offering is managed by Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities, with underwriters granted a 30-day option to purchase an additional 1.155 million ADSs at the offering price, which enhances market confidence in the transaction.
- Transaction Timeline: The offering is expected to close on June 23, 2026, subject to customary closing conditions, providing investors with a clear timeline that aids in market transparency and planning.
- Market Performance: Over the past year, LEGN shares have traded between $16.24 and $45.30, closing at $33.52, although they fell 5.43% to $31.70 in overnight trading, yet the overall performance reflects a degree of market vitality.
See More
Biotech M&A Surge Resumes with Major Deals
- M&A Market Revival: According to a PwC report, the pharmaceutical and life sciences sector saw over $65 billion in mergers and acquisitions in Q1 2023, marking the best quarter since 2020 and indicating a significant uptick in market activity.
- Legend Biotech's Growth Potential: Legend Biotech's Carvykti therapy generated $597 million in sales in Q1, a 62% year-over-year increase, with projections suggesting annual sales could exceed $5 billion, making it an attractive acquisition target for larger pharmaceutical companies.
- BioNTech's Clinical Trial Progress: Despite a 35.4% year-over-year revenue decline to €118.1 million, BioNTech is running over 25 phase 2 and phase 3 clinical trials, showcasing a mature oncology portfolio that could attract acquisition interest.
- Acquisition Risks and Opportunities: Although both Legend Biotech and BioNTech have seen their shares drop over 13% in the past year, their unique technologies and product lines present significant potential upside for large pharmaceutical companies facing patent cliffs, making acquisitions a strategic consideration.
See More
Pharmaceutical Sector Sees $65 Billion in M&A Activity in Q1 2023
- M&A Activity Resurgence: According to PwC, the pharmaceutical and life sciences sector saw over $65 billion in mergers and acquisitions in Q1 2023, marking the best quarter since 2020 and indicating a robust recovery in the industry.
- Major Deal Examples: In Q2, Sun Pharmaceuticals announced its acquisition of Organon for $11.75 billion, while AbbVie reported its acquisition of Apogee Therapeutics for $10.9 billion in June, reflecting large pharma's strong interest in biotech companies and enhancing market activity.
- Market Potential of Legend Biotech: Legend Biotech's Carvykti therapy generated $597 million in sales in Q1, up 62% year-over-year, with projected annual sales potentially exceeding $5 billion, showcasing its competitive strength in the oncology treatment landscape.
- Financial Attractiveness of BioNTech: Despite a 35.4% year-over-year revenue decline to €118.1 million, BioNTech holds €16.8 billion in cash and equivalents, making it an appealing acquisition target, particularly with its mature oncology portfolio and upcoming clinical trials.
See More
Calidi Biotherapeutics Appoints New Independent Director
- New Board Member: Calidi Biotherapeutics announced the appointment of Corsee Sanders as an independent director effective June 17, 2026, leveraging her 23 years of leadership experience at Genentech/Roche to provide strategic guidance.
- Extensive Industry Background: Sanders previously served as Executive Vice President of Development Operations at Juno and acted as a strategic advisor to the Chief Medical Officer post-Celgene acquisition, highlighting her deep expertise in the biopharmaceutical sector.
- Current Board Positions: Currently, Sanders holds board positions at Legend Biotech, Ultragenyx Pharmaceutical, and AltruBio, further enhancing her influence within the biotechnology industry.
- Stock Price Fluctuation: Calidi's stock has traded between $0.12 and $19.20 over the past year, closing at $0.1560, indicating a cautious market sentiment regarding the company's future prospects.
See More
Stock Futures Rise Modestly; Rumble and Others Show Strong Performance
- Rumble's New Business Unit: Rumble (RUM) shares surged 17% after the company launched a new business unit following its acquisition of Northern Data AG, with FY revenue outlook raised by approximately 30% to between €170 million and €190 million, enhancing its competitive position in the market.
- Smith & Wesson's Strong Earnings: Smith & Wesson Brands (SWBI) saw a 14% increase in shares after reporting a quarterly performance that exceeded expectations, with net sales up nearly 27% year-over-year and adjusted EBITDAS rising 31.7%, while planning investments in its Springfield facility for FY 2027 to boost capacity and operational efficiency.
- Spero Therapeutics Drug Approval: Spero Therapeutics (SPRO) shares rose 11% following FDA approval of Utebzi, developed in partnership with GSK, marking the first oral carbapenem therapy for complicated urinary tract infections, which is expected to significantly increase its market share.
- D-Wave's Quantum Computing Simulator: D-Wave Quantum (QBTS) shares gained 4% after unveiling its first gate-model quantum computing simulator designed for error-aware programming, representing a technological advancement that may attract more developers to its innovative solutions.
See More
Legend Biotech Prices Public Offering of 7.7M ADSs
- Offering Size: Legend Biotech has announced the pricing of 7.7 million American Depositary Shares (ADSs) at $29.35 each, with total gross proceeds expected to be approximately $226 million, which will significantly bolster the company's capital structure.
- Underwriter Arrangement: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are acting as joint book-running managers for the transaction, indicating strong market confidence in the company's financing capabilities and laying the groundwork for future capital operations.
- Overallotment Option: Legend Biotech has granted underwriters a 30-day overallotment option to purchase up to an additional 1.16 million ADSs at the public offering price, providing the company with flexibility for further financing.
- Market Reaction: Following the announcement of the offering, Legend Biotech's shares fell 6% in after-hours trading on Wednesday, reflecting a cautious market sentiment regarding the financing, which may impact the company's short-term stock performance.
See More
Legend Biotech Prices Public Offering at $29.35 per ADS
- Offering Size: Legend Biotech has priced its public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 each, raising approximately $226 million in gross proceeds before underwriting discounts and expenses, indicating strong demand in the capital markets.
- Underwriter Arrangement: The offering is managed by Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities, with underwriters granted a 30-day option to purchase an additional 1.155 million ADSs at the offering price, which enhances market confidence in the transaction.
- Transaction Timeline: The offering is expected to close on June 23, 2026, subject to customary closing conditions, providing investors with a clear timeline that aids in market transparency and planning.
- Market Performance: Over the past year, LEGN shares have traded between $16.24 and $45.30, closing at $33.52, although they fell 5.43% to $31.70 in overnight trading, yet the overall performance reflects a degree of market vitality.
See More
